+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinal Disorder Treatment Market - Global Forecast to 2030- Product Image
Retinal Disorder Treatment Market - Global Forecast to 2030- Product Image
Sale

Retinal Disorder Treatment Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6012391
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Retinal Disorder Treatment Market grew from USD 9.38 billion in 2024 to USD 10.27 billion in 2025. It is expected to continue growing at a CAGR of 8.97%, reaching USD 15.72 billion by 2030.

The landscape of retinal disorder treatments is evolving at an unprecedented pace, driven by breakthroughs in pharmacology, advancements in surgical interventions, and shifting healthcare policies. As populations age and the prevalence of conditions such as age-related macular degeneration and diabetic retinopathy climbs, stakeholders from clinicians and pharmaceutical innovators to payers and policymakers must stay abreast of emerging developments. This executive summary offers a concise yet comprehensive overview of critical market dynamics, emerging technologies, and regulatory currents shaping treatment paradigms. It seeks to inform decision-makers about the transformational forces redefining patient outcomes and to highlight strategic considerations for sustaining competitive advantage in a rapidly changing environment. By synthesizing the most salient industry data with expert insights, the summary underscores opportunities for collaboration, investment, and innovation without delving into market sizing or forecasting. Whether you are evaluating portfolio expansion, assessing partnership prospects, or exploring novel therapeutic modalities, this introduction lays the groundwork for a deeper understanding of the sector’s trajectory and the strategic implications for all stakeholders.

Transformative Shifts in the Retinal Treatment Landscape

In recent years, the retinal treatment landscape has undergone transformative shifts catalyzed by technological, regulatory, and patient-centric drivers. Advanced imaging modalities and artificial intelligence-enabled diagnostics are empowering clinicians to detect pathology with greater precision, thereby enabling earlier interventions that improve visual outcomes. Concurrently, novel drug delivery systems-ranging from sustained-release implants to gene therapy vectors-are redefining treatment frequency and adherence profiles. On the regulatory front, streamlined approval pathways and adaptive trial designs have accelerated time to market for breakthrough therapies, fostering a more dynamic innovation ecosystem.

Moreover, the growing emphasis on patient experience has prompted the integration of telehealth services and remote monitoring solutions, bridging geographical gaps in access to specialized retinal care. Health economics and outcomes research are now at the forefront of value-based contracting, incentivizing providers to demonstrate real-world efficacy and cost effectiveness. These converging trends have collectively elevated the standard of care, positioning retinal disorder treatment at the intersection of precision medicine and digital health.

Cumulative Impact of United States Tariffs on Retail Treatment Supply Chains

The implementation of new United States tariffs in 2025 has introduced a multifaceted impact on the retinal treatment ecosystem. By imposing additional duties on imported pharmaceuticals, active pharmaceutical ingredients, and specialized medical devices, the policy has exerted upward pressure on production and procurement costs. Manufacturers reliant on global supply chains have had to reassess sourcing strategies, often redirecting procurement towards domestic suppliers or adjusting formulation processes to mitigate cost escalation.

These tariff-driven cost headwinds have also reverberated through hospital and clinic budgets, prompting some institutions to renegotiate vendor contracts or explore alternative treatment modalities with lower material expenses. In parallel, payers have become increasingly vigilant in scrutinizing reimbursement criteria, leveraging real-world evidence to validate therapeutic value. Although the tariffs aim to bolster domestic manufacturing, the short-term consequence has been a recalibration of pricing structures and an intensified focus on supply-chain resilience. Looking ahead, continued dialogue among industry stakeholders, policymakers, and patient advocacy groups will be essential to balance trade policy objectives with the imperative of delivering affordable, high-quality care.

Key Segmentation Insights Across Treatment Types, Modalities, and Patient Profiles

A nuanced understanding of market segmentation sheds light on evolving demand patterns and investment priorities. By treatment type, the market encompasses injections, laser therapy, and surgical procedures, where injections divide into anti-VEGF and steroid categories, and each of those further stratifies into agents such as aflibercept, bevacizumab, ranibizumab, dexamethasone implants, and triamcinolone acetonide; laser therapy comprises focal and grid photocoagulation techniques; and surgical interventions include retinal detachment surgery, scleral buckling, and vitrectomy. When viewed through the lens of drug class, corticosteroids split into intravitreal and oral formulations, monoclonal antibodies focus on anti-VEGF agents, and NSAIDs differentiate between oral and topical applications. From a development stage perspective, clinical trials progress through phases I to IV, while preclinical work spans in vitro studies and in vivo animal models. Patient demographics segment the market by age group-adult, geriatric, pediatric-gender categories, and condition severity from mild to severe. End-users range from ambulatory surgical centers to hospitals-both private and public-ophthalmic clinics including specialized retinal centers, and research institutes that cover academic and contract research organizations. Finally, condition-based segmentation addresses AMD (dry and wet forms), diabetic retinopathy (non-proliferative and proliferative), macular edema, retinal detachment, and retinal vein occlusion with branch and central subtypes. This layered segmentation framework reveals areas of unmet need, highlights high-growth niches, and informs targeted R&D investment strategies.

Key Regional Insights Shaping Treatment Adoption and Access

Regional dynamics are playing a pivotal role in shaping the global retinal treatment market. In the Americas, robust healthcare infrastructure, broad access to advanced diagnostics, and an active pipeline of novel therapeutics underpin strong adoption rates, particularly in the United States and Canada. The region’s emphasis on value-based care is driving partnerships between pharmaceutical companies and provider networks to collect and leverage real-world evidence.

Across Europe, the Middle East & Africa, heterogeneous regulatory frameworks coexist with emerging reimbursement models. Western European countries benefit from centralized approval processes and established patient registries, while EMEA’s growth potential lies in expanding access to underserved markets in the Middle East and Africa. Collaborative research consortia and public-private partnerships are facilitating knowledge transfer and capacity building in these regions.

In the Asia-Pacific region, rapid urbanization and rising healthcare expenditures are accelerating market penetration of both branded and biosimilar therapies. Countries such as Japan, South Korea, and China are investing heavily in local manufacturing and clinical trial infrastructure. Additionally, tele-ophthalmology initiatives and government-sponsored screening programs are enhancing early detection and referral pathways, further bolstering market growth.

Key Company Insights into Portfolio Strategies and Innovation

Leading companies are driving innovation through diverse portfolios that span pharmaceuticals, biologics, and advanced delivery systems. AbbVie Inc. is leveraging its expertise in anti-VEGF therapies to expand indications, while Abeona Therapeutics Inc. explores gene therapy approaches targeting inherited retinal diseases. Apellis Pharmaceuticals, Inc. has introduced complement inhibitors with novel mechanisms, and Bausch & Lomb Incorporated is advancing sustained-release implant technologies. Bayer AG continues to refine its aflibercept franchise, while F. Hoffmann-La Roche Ltd. integrates real-world data into precision dosing regimens.

Graybug Vision Inc. is pioneering micro-implant platforms, and Kubota Pharmaceutical Holdings Co., Ltd. focuses on minimally invasive formulations. Novartis AG maintains a broad pipeline across biologics and small molecules, and ONL Therapeutics emphasizes neuroprotective agents for retinal ganglion cells. Opthea pursues next-generation VEGF receptor blockers, whereas Oxford Biomedica PLC specializes in viral vector manufacturing. Oxurion NV develops small-molecule inhibitors of vascular leakage, and Pfizer, Inc. applies its global reach to accelerate drug launches. Regeneron Pharmaceuticals Inc. has refined its portfolio with innovative delivery devices, and Santen Pharmaceutical Co., Ltd. drives ophthalmic research in Asia. Spark Therapeutics, Inc. rounds out the competitive landscape with targeted gene editing platforms. Collectively, these organizations are setting new benchmarks in safety, efficacy, and patient experience.

Actionable Recommendations for Industry Leaders to Enhance Competitiveness

Industry leaders should pursue several strategic actions to capitalize on evolving market dynamics. First, invest in integrated diagnostics and digital health platforms to enhance early detection and personalized treatment pathways. Second, develop strategic alliances with academic centers and regulatory agencies to expedite adaptive trial designs and real-world data collection. Third, optimize supply-chain resilience by diversifying sourcing strategies and exploring local manufacturing partnerships, mitigating tariff-related cost pressures. Fourth, engage payers through outcomes-based contracting models that demonstrate long-term value beyond visual acuity improvements. Finally, prioritize patient-centric initiatives-such as remote monitoring and adherence support programs-to differentiate offerings and foster loyalty among care providers and patients.

Conclusion: Seizing Opportunities in an Evolving Treatment Ecosystem

In summary, the retinal disorder treatment market stands at a pivotal juncture defined by rapid technological innovation, evolving regulatory landscapes, and shifting economic policies. Stakeholders who integrate cutting-edge diagnostics, leverage advanced delivery systems, and embrace collaborative models will be best positioned to deliver meaningful clinical and economic value. By aligning R&D priorities with patient-centred outcomes, refining commercialization strategies through regional customization, and navigating policy-driven cost dynamics, organizations can secure sustainable growth. As the sector continues to mature, ongoing vigilance and agility will remain essential to address emerging challenges and to seize new opportunities that improve patient vision and quality of life.

Market Segmentation & Coverage

This research report categorizes the Retinal Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Injections
    • Anti-VEGF Injections
      • Aflibercept Injections
      • Bevacizumab Injections
      • Ranibizumab Injections
    • Steroid Injections
      • Dexamethasone Implant
      • Triamcinolone Acetonide
  • Laser Therapy
    • Focal Laser Photocoagulation
    • Grid Laser Photocoagulation
  • Surgical Procedures
    • Retinal Detachment Surgery
    • Scleral Buckling
    • Vitrectomy
  • Corticosteroids
    • Intravitreal Corticosteroids
    • Oral Corticosteroids
  • Monoclonal Antibodies
    • Anti-VEGF Agents
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Oral NSAIDs
    • Topical NSAIDs
  • Clinical Trials
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Preclinical Trials
    • In Vitro Studies
    • In Vivo Animal Models
  • Age Group
    • Adult
    • Geriatric
    • Pediatric
  • Gender
    • Female
    • Male
  • Severity of Condition
    • Mild
    • Moderate
    • Severe
  • Ambulatory Surgical Centers
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Ophthalmic Clinics
    • Specialized Retinal Clinics
  • Research Institutes
    • Academic Research Institutes
    • Contract Research Organizations
  • Age-Related Macular Degeneration (AMD)
    • Dry AMD
    • Wet AMD
  • Diabetic Retinopathy
    • Non-Proliferative Diabetic Retinopathy (NPDR)
    • Proliferative Diabetic Retinopathy (PDR)
  • Macular Edema
  • Retinal Detachment
  • Retinal Vein Occlusion
    • Branch Retinal Vein Occlusion
    • Central Retinal Vein Occlusion

This research report categorizes the Retinal Disorder Treatment Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Retinal Disorder Treatment Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Graybug Vision Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Novartis AG
  • ONL Therapeutics
  • Opthea
  • Oxford Biomedica PLC
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinal Disorder Treatment Market, by Treatment Type
8.1. Introduction
8.2. Injections
8.2.1. Anti-VEGF Injections
8.2.1.1. Aflibercept Injections
8.2.1.2. Bevacizumab Injections
8.2.1.3. Ranibizumab Injections
8.2.2. Steroid Injections
8.2.2.1. Dexamethasone Implant
8.2.2.2. Triamcinolone Acetonide
8.3. Laser Therapy
8.3.1. Focal Laser Photocoagulation
8.3.2. Grid Laser Photocoagulation
8.4. Surgical Procedures
8.4.1. Retinal Detachment Surgery
8.4.2. Scleral Buckling
8.4.3. Vitrectomy
9. Retinal Disorder Treatment Market, by Drug Class
9.1. Introduction
9.2. Corticosteroids
9.2.1. Intravitreal Corticosteroids
9.2.2. Oral Corticosteroids
9.3. Monoclonal Antibodies
9.3.1. Anti-VEGF Agents
9.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
9.4.1. Oral NSAIDs
9.4.2. Topical NSAIDs
10. Retinal Disorder Treatment Market, by Development Stage
10.1. Introduction
10.2. Clinical Trials
10.2.1. Phase I
10.2.2. Phase II
10.2.3. Phase III
10.2.4. Phase IV
10.3. Preclinical Trials
10.3.1. In Vitro Studies
10.3.2. In Vivo Animal Models
11. Retinal Disorder Treatment Market, by Patient Demographics
11.1. Introduction
11.2. Age Group
11.2.1. Adult
11.2.2. Geriatric
11.2.3. Pediatric
11.3. Gender
11.3.1. Female
11.3.2. Male
11.4. Severity of Condition
11.4.1. Mild
11.4.2. Moderate
11.4.3. Severe
12. Retinal Disorder Treatment Market, by End-User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.3.1. Private Hospitals
12.3.2. Public Hospitals
12.4. Ophthalmic Clinics
12.4.1. Specialized Retinal Clinics
12.5. Research Institutes
12.5.1. Academic Research Institutes
12.5.2. Contract Research Organizations
13. Retinal Disorder Treatment Market, by Condition Treated
13.1. Introduction
13.2. Age-Related Macular Degeneration (AMD)
13.2.1. Dry AMD
13.2.2. Wet AMD
13.3. Diabetic Retinopathy
13.3.1. Non-Proliferative Diabetic Retinopathy (NPDR)
13.3.2. Proliferative Diabetic Retinopathy (PDR)
13.4. Macular Edema
13.5. Retinal Detachment
13.6. Retinal Vein Occlusion
13.6.1. Branch Retinal Vein Occlusion
13.6.2. Central Retinal Vein Occlusion
14. Americas Retinal Disorder Treatment Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Retinal Disorder Treatment Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Retinal Disorder Treatment Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Abeona Therapeutics Inc.
17.3.3. Apellis Pharmaceuticals, Inc.
17.3.4. Bausch & Lomb Incorporated
17.3.5. Bayer AG
17.3.6. F. Hoffmann-La Roche Ltd.
17.3.7. Graybug Vision Inc.
17.3.8. Kubota Pharmaceutical Holdings Co., Ltd.
17.3.9. Novartis AG
17.3.10. ONL Therapeutics
17.3.11. Opthea
17.3.12. Oxford Biomedica PLC
17.3.13. Oxurion NV
17.3.14. Pfizer, Inc.
17.3.15. Regeneron Pharmaceuticals Inc.
17.3.16. Santen Pharmaceutical Co., Ltd.
17.3.17. Spark Therapeutics, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RETINAL DISORDER TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. RETINAL DISORDER TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. RETINAL DISORDER TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RETINAL DISORDER TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RETINAL DISORDER TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RETINAL DISORDER TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AFLIBERCEPT INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BEVACIZUMAB INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RANIBIZUMAB INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEXAMETHASONE IMPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TRIAMCINOLONE ACETONIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY FOCAL LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GRID LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL DETACHMENT SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SCLERAL BUCKLING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY INTRAVITREAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ORAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY TOPICAL NSAIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY IN VITRO STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY IN VIVO ANIMAL MODELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY SPECIALIZED RETINAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), BY REGION, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRY AMD, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY WET AMD, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 83. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR), BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY PROLIFERATIVE DIABETIC RETINOPATHY (PDR), BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL DETACHMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 101. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 102. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 103. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 104. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 116. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 153. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 154. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 155. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 156. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 157. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 158. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 160. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 161. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 163. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 164. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 165. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 166. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 167. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 168. BRAZIL RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 169. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 170. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 171. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 172. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 173. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 174. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 175. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 176. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 177. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 178. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 179. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 180. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 181. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 182. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 183. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 184. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 185. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 186. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 187. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 189. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 190. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 191. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 192. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 193. CANADA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 194. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 195. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 197. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 198. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 199. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 200. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 201. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 202. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 203. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 204. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 205. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 206. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 207. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 208. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 209. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 210. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 211. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 213. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 214. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 215. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 216. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 217. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 218. MEXICO RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 219. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 220. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 221. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 222. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 223. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 224. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 225. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 226. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 227. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 228. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 229. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 230. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 231. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 232. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 233. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 234. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 235. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 236. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 238. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 239. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 240. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 241. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 242. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 243. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 244. UNITED STATES RETINAL DISORDER TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 245. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 247. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 248. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 249. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 250. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 251. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 252. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 253. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 255. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 256. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 257. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC RETINAL DISORDER TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 272. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 273. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 274. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 275. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 276. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 277. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 278. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 279. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 280. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
TABLE 281. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 282. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 283. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY PRECLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 284. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 285. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 287. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY SEVERITY OF CONDITION, 2018-2030 (USD MILLION)
TABLE 288. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 290. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY OPHTHALMIC CLINICS, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 292. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY CONDITION TREATED, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION (AMD), 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY DIABETIC RETINOPATHY, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA RETINAL DISORDER TREATMENT MARKET SIZE, BY RETINAL VEIN OCCLUSION, 2018-2030 (USD MILLION)
TABLE 296. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 297. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY INJECTIONS, 2018-2030 (USD MILLION)
TABLE 298. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTIONS, 2018-2030 (USD MILLION)
TABLE 299. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY STEROID INJECTIONS, 2018-2030 (USD MILLION)
TABLE 300. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2030 (USD MILLION)
TABLE 301. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2030 (USD MILLION)
TABLE 302. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 303. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
TABLE 304. CHINA RETINAL DISORDER TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (U

Companies Mentioned

  • AbbVie Inc.
  • Abeona Therapeutics Inc.
  • Apellis Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Graybug Vision Inc.
  • Kubota Pharmaceutical Holdings Co., Ltd.
  • Novartis AG
  • ONL Therapeutics
  • Opthea
  • Oxford Biomedica PLC
  • Oxurion NV
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Spark Therapeutics, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Retinal Disorder Treatment Market Report 2025 - Product Image

Retinal Disorder Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Retinal Disorder Treatment - Global Strategic Business Report - Product Image

Retinal Disorder Treatment - Global Strategic Business Report

  • Report
  • 66 Pages
  • Global
From
Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Ophthalmic Disease Therapeutics Market (2024 Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 253 Pages
  • Global
From
Retinal Imaging Devices Market Size, Share & Trends Analysis Report By Device (Optical Coherence Tomography (OCT) Devices, Fundus Cameras), By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Retinal Imaging Devices Market Size, Share & Trends Analysis Report By Device (Optical Coherence Tomography (OCT) Devices, Fundus Cameras), By Application, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 220 Pages
  • Global
From
Ophthalmic Equipment Market Overview, 2025-30 - Product Image

Ophthalmic Equipment Market Overview, 2025-30

  • Report
  • 110 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.